Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

JOURNAL ARTICLE published June 2017 in The Lancet

Authors: Anthony B El-Khoueiry | Bruno Sangro | Thomas Yau | Todd S Crocenzi | Masatoshi Kudo | Chiun Hsu | Tae-You Kim | Su-Pin Choo | Jörg Trojan | Theodore H Welling | Tim Meyer | Yoon-Koo Kang | Winnie Yeo | Akhil Chopra | Jeffrey Anderson | Christine dela Cruz | Lixin Lang | Jaclyn Neely | Hao Tang | Homa B Dastani | Ignacio Melero